Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KAI$270.87+5.07(+1.91%)Kadant to Hold Earnings Conference Call on Wednesday, November 4, 2026[12:02:20 PM ET]IPX$17.10+1.51(+9.69%)IperionX Webinar – Investor Update[12:00:00 PM ET]DDOG$261.63-16.78(-6.03%)Datadog Named a Leader in AIOps Platforms Research[12:00:00 PM ET]AGNT$3.95+0.03(+0.77%)Arizona's MHG Commercial Joins eXp Commercial With 18 Advisors and $435 Million in Closed Transactions[12:00:00 PM ET]FMCC$4.05+0.40(+11.13%)Mortgage Rates Decline Further to 7.24%[12:00:00 PM ET]EXLS$40.76+0.04(+0.09%)EXL named an OpenAI Select Partner[11:56:23 AM ET]DCOM$42.35+0.48(+1.16%)Dime Supports Local Moriches Bay Project[11:47:13 AM ET]MTX$62.75+0.82(+1.32%)Fortune Minerals Provides NICO Feasibility Study Update[11:45:00 AM ET]NRSN$2.19-0.17(-7.24%)NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a biotechnology company developing treatments for neurodegenerative...[11:30:00 AM ET]PRKS$31.72+0.72(+2.32%)BUSCH GARDENS' AWARD-WINNING CHRISTMAS TOWN RETURNS WITH MILLIONS OF LIGHTS, ALL-NEW ENTERTAINMENT AND FESTIVE FUN AT ITS TWO SPECTACULAR PARKS The most wonderful time of the year is almost here, and Busch Gardens Christmas Town™ is ready to make it brighter than ever. Beginning Nov. 13, both ...[11:30:00 AM ET]DYNC$10.91+0.01(+0.09%)Dynamix Corporation Announces Its Intention to Liquidate[11:30:00 AM ET]PRKS$31.72+0.72(+2.32%)SEAWORLD'S AWARD-WINNING CHRISTMAS CELEBRATION RETURNS IN ORLANDO, SAN DIEGO AND SAN ANTONIO WITH ALL-NEW FESTIVE ENTERTAINMENT AND TIMELESS HOLIDAY JOY The most wonderful time of the year is almost here, and SeaWorld is ready to shine. This holiday season, SeaWorld Orlando, SeaWorld San Diego and...[11:25:00 AM ET]CRVW$0.03+0.00(+8.92%)CareView Communications Announces New Business Agreement with San Juan Regional Medical Center[11:20:00 AM ET]ARAI$0.11+0.00(+1.00%)Arrive AI Installs First Arrive Point(TM) Units in Commercial Office Building in Central Indiana[11:11:00 AM ET]

PTGX · NASDAQ

Protagonist Therapeutics, Inc.

$145.28 +3.09 (+2.17%)

Company overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral alpha-4-beta-7 integrin-specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$9.4B
Employees
124
Headquarters
Newark, CA
Website
protagonist-inc.com
CEO
Dinesh V. Patel
Listed
August 11, 2016
P/E
-80.63
Dividend yield
0.00%

Company financials

Revenue
$74.1M
Gross profit
$73.7M
Operating income
-$142M
EBITDA
-$134M
Net income
-$115M
EPS
-$1.80
Total assets
$697M
Total debt
$9.8M
Gross margin
99.45%
Net margin
-154.88%
Earnings yield
-1.24%

Revenue segmentation

By product (FY 2024)
By region (FY 2024)

No geographic segmentation.

Showing FY 2024

Price chart

90.03108.40126.78145.16163.53
PTGX 1D NASDAQ O139.35H143.25L138.29C142.19+1.07 (+0.76%)Vol86.35K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks Investment Research
PTGXProtagonist Therapeutics, Inc. Stock news Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term Zacks Investment Research
PTGXProtagonist Therapeutics, Inc. Stock news Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? Zacks Investment Research
PTGXProtagonist Therapeutics, Inc. Press release Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026 ACCESS Newswire
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder Seeking Alpha
PTGXProtagonist Therapeutics, Inc. Press release A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a... PR Newswire
PTGXProtagonist Therapeutics, Inc. Stock news Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX) Defense World
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know Zacks Investment Research
VUG Stock news Which Growth-Focused ETF is the Better Fit? Vanguard Morningstar Growth (VUG) or SPDR Small Cap Growth ETF (SLYG)? The Motley Fool
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review Defense World
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stock Defense World
PTGXProtagonist Therapeutics, Inc. Stock news Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX Defense World
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
PTGXProtagonist Therapeutics, Inc. Press release Protagonist Therapeutics Announces $300 Million Share Repurchase Program ACCESS Newswire
PTGXProtagonist Therapeutics, Inc. Press release Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 ACCESS Newswire
AAPL Stock news Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript Seeking Alpha
PTGXProtagonist Therapeutics, Inc. Stock news Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment MarketBeat
PTGXProtagonist Therapeutics, Inc. Stock news Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. The Motley Fool
VUG Stock news Better Growth Stock ETF: Vanguard's Large-Cap VUG vs. Invesco's Small-Cap RZG The Motley Fool
See more
FAQ

Questions about Protagonist Therapeutics, Inc.

What does Protagonist Therapeutics, Inc. do?
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral alpha-4-beta-7 integrin-specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc.
What is PTGX's market cap?
Protagonist Therapeutics, Inc. (PTGX) is a listed stock with a live quote. The latest market cap on this page is $9.4B.
Where is Protagonist Therapeutics, Inc. headquartered?
Protagonist Therapeutics, Inc. is headquartered in Newark, CA.
How do I get PTGX news from the API?
Call GET /v1/news?tickers=PTGX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does PTGX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PTGX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the PTGX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs